Izumi Y, Kim S, Namba M, Yasumoto H, Miyazaki H, Hoshiga M, Kaneda Y, Morishita R, Zhan Y, Iwao H
Department of Pharmacology, Osaka City University Medical School, Osaka, Japan.
Circ Res. 2001 Jun 8;88(11):1120-6. doi: 10.1161/hh1101.091267.
We previously reported that extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK), belonging to mitogen-activated protein kinases, are rapidly activated in balloon-injured artery. Therefore, we examined the role of these kinase activations in neointimal formation by using an in vivo gene transfer technique. We made the dominant-negative mutants of ERK (DN-ERK) and JNK (DN-JNK) to specifically inhibit endogenous ERK and JNK activation, respectively. Before balloon injury, these mutants were transfected into rat carotid artery using the hemagglutinating virus of Japan liposome method. In vivo transfection of DN-ERK and DN-JNK significantly suppressed the activation of ERK and JNK, respectively, after balloon injury, confirming successful expression of the transfected genes. Neointimal formation at 14 and 28 days after injury was prevented by gene transfer of DN-ERK or DN-JNK. Furthermore, bromodeoxyuridine labeling index and total cell-counting analysis at 7 days showed that either DN-ERK or DN-JNK remarkably suppressed smooth muscle cell (SMC) proliferation in both the intima and the media after injury. Gene transfer of wild-type ERK (W-ERK) or JNK (W-JNK) significantly enhanced neointimal hyperplasia at 14 days after injury. Furthermore, DN-ERK and DN-JNK significantly suppressed serum-induced SMC proliferation in vitro. We obtained the first evidence that in vivo gene transfer of DN-ERK or DN-JNK prevented neointimal formation in balloon-injured artery by inhibiting SMC proliferation. Thus, ERK and JNK activation triggers SMC proliferation, leading to neointimal formation. These kinases may be the new therapeutic targets for prevention of vascular diseases.
我们之前报道过,属于丝裂原活化蛋白激酶的细胞外信号调节激酶(ERK)和c-Jun氨基末端激酶(JNK)在球囊损伤的动脉中会迅速被激活。因此,我们通过使用体内基因转移技术来研究这些激酶激活在新生内膜形成中的作用。我们制备了ERK(DN-ERK)和JNK(DN-JNK)的显性负性突变体,以分别特异性抑制内源性ERK和JNK的激活。在球囊损伤前,使用日本血凝病毒脂质体方法将这些突变体转染到大鼠颈动脉中。体内转染DN-ERK和DN-JNK分别在球囊损伤后显著抑制了ERK和JNK的激活,证实了转染基因的成功表达。损伤后14天和28天的新生内膜形成通过DN-ERK或DN-JNK的基因转移得到了预防。此外,损伤后7天的溴脱氧尿苷标记指数和总细胞计数分析表明,DN-ERK或DN-JNK均显著抑制了损伤后内膜和中膜平滑肌细胞(SMC)的增殖。野生型ERK(W-ERK)或JNK(W-JNK)的基因转移在损伤后14天显著增强了新生内膜增生。此外,DN-ERK和DN-JNK在体外显著抑制了血清诱导的SMC增殖。我们获得了首个证据,即DN-ERK或DN-JNK的体内基因转移通过抑制SMC增殖预防了球囊损伤动脉中的新生内膜形成。因此,ERK和JNK激活触发SMC增殖,导致新生内膜形成。这些激酶可能是预防血管疾病的新治疗靶点。